221 related articles for article (PubMed ID: 36802397)
1. Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden.
Nordström P; Ballin M; Nordström A
PLoS Med; 2023 Feb; 20(2):e1004127. PubMed ID: 36802397
[TBL] [Abstract][Full Text] [Related]
2. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
3. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
[TBL] [Abstract][Full Text] [Related]
5. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
6. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
[TBL] [Abstract][Full Text] [Related]
8. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
Hansen CH; Friis NU; Bager P; Stegger M; Fonager J; Fomsgaard A; Gram MA; Christiansen LE; Ethelberg S; Legarth R; Krause TG; Ullum H; Valentiner-Branth P
Lancet Infect Dis; 2023 Feb; 23(2):167-176. PubMed ID: 36270311
[TBL] [Abstract][Full Text] [Related]
9. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Casado I; Navascués A; Burgui C; Ezpeleta C; Castilla J; Guevara M; ;
Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729113
[TBL] [Abstract][Full Text] [Related]
10. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet; 2022 Feb; 399(10327):814-823. PubMed ID: 35131043
[TBL] [Abstract][Full Text] [Related]
11. Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.
Zambrano LD; Newhams MM; Simeone RM; Payne AB; Wu M; Orzel-Lockwood AO; Halasa NB; Calixte JM; Pannaraj PS; Mongkolrattanothai K; Boom JA; Sahni LC; Kamidani S; Chiotos K; Cameron MA; Maddux AB; Irby K; Schuster JE; Mack EH; Biggs A; Coates BM; Michelson KN; Bline KE; Nofziger RA; Crandall H; Hobbs CV; Gertz SJ; Heidemann SM; Bradford TT; Walker TC; Schwartz SP; Staat MA; Bhumbra SS; Hume JR; Kong M; Stockwell MS; Connors TJ; Cullimore ML; Flori HR; Levy ER; Cvijanovich NZ; Zinter MS; Maamari M; Bowens C; Zerr DM; Guzman-Cottrill JA; Gonzalez I; Campbell AP; Randolph AG;
MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):330-338. PubMed ID: 38635481
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada.
Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Fafard J; Gilca R; Talbot D; Ouakki M; Febriani Y; Deceuninck G; De Wals P; De Serres G
Lancet Healthy Longev; 2023 Aug; 4(8):e409-e420. PubMed ID: 37459879
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
[TBL] [Abstract][Full Text] [Related]
14. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.
Bager P; Wohlfahrt J; Bhatt S; Stegger M; Legarth R; Møller CH; Skov RL; Valentiner-Branth P; Voldstedlund M; Fischer TK; Simonsen L; Kirkby NS; Thomsen MK; Spiess K; Marving E; Larsen NB; Lillebaek T; Ullum H; Mølbak K; Krause TG;
Lancet Infect Dis; 2022 Jul; 22(7):967-976. PubMed ID: 35468331
[TBL] [Abstract][Full Text] [Related]
15. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
Liu B; Gidding H; Stepien S; Cretikos M; Macartney K
Vaccine; 2022 Oct; 40(43):6288-6294. PubMed ID: 36180375
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
17. mRNA SARS-CoV-2 Vaccination Before vs During Pregnancy and Omicron Infection Among Infants.
Goh O; Pang D; Tan J; Lye D; Chong CY; Ong B; Tan KB; Yung CF
JAMA Netw Open; 2023 Nov; 6(11):e2342475. PubMed ID: 37948079
[TBL] [Abstract][Full Text] [Related]
18. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL
JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146
[TBL] [Abstract][Full Text] [Related]
19. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
[TBL] [Abstract][Full Text] [Related]
20. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]